Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.72 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.72 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL29172594 | 0.97 | CYP4F2 (0.68) | CYP4F2CYP4A11CYP4Z1MAPTKMT2A | |
| SCHEMBL18011670 | 0.92 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1MAPTKMT2A | |
| SCHEMBL68902 | 0.91 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1MAPTTDP1 | |
| SCHEMBL2291044 | 0.90 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1MAPTKMT2A | |
| Trifluoroacetic Acid SCHEMBL27484103 | 0.89 | CYP4F2 (0.59) | CYP4F2CYP4A11CYP4Z1MAPTKMT2A | |
| SCHEMBL6781618 | 0.86 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1MAPTALDH1A1 | |
| SCHEMBL4887611 | 0.86 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1MAPTALDH1A1 | |
| SCHEMBL10206072 | 0.85 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1MAPTTDP1 | |
| SCHEMBL363982 | 0.85 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1MAPTALDH1A1 | |
| SCHEMBL879130 | 0.85 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113980117-B | Fenpyroximate antigen and preparation method and application thereof | 西南大学 | 2024-07-12 | — | — | CN | claimed |
| CN-117820460-A | Methoxypiperidine ethyl antigen and preparation method and application thereof | 西南大学 | 2024-04-05 | — | — | CN | claimed |
| CN-116425739-A | Compound for tumor targeted imaging and photodynamic therapy and synthesis method and application thereof | 浙江义氪生物科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2025-08-26 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4469441-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | Parion Sciences, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-116425739-B | Compound for tumor targeted imaging and photodynamic therapy and synthesis method and application thereof | 浙江义氪生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-113980117-B | Fenpyroximate antigen and preparation method and application thereof | 西南大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-118063326-A | Method for promoting nickel catalysis to synthesize arylamine compound by red light | 陕西师范大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-117820460-A | Methoxypiperidine ethyl antigen and preparation method and application thereof | 西南大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-0636127-B1 | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6090826-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5750693-A | THIOCHROMANYL OR CHROMANYL COMPOUNDS AS ANTICARCINOGINIC AGENTS, SKIN DISORDERS AND ATHEROSCLEROSIS | ALLERGAN (US) | 1998-05-12 | — | — | US | disclosed |
| US-5677451-A | CONTROLLING CELL DIFFERENTIATION; SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1997-10-14 | — | — | US | disclosed |
| US-5663347-A | REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS; ANTICARCINOGNIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| US-5468879-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0636127-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROBICYCLIC GROUPS AND HETEROAROMATIC OR PHENYL GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC. (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5264578-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993016068-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROBICYCLIC GROUPS AND HETEROAROMATIC OR PHENYL GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | CYP4F2 2130/4885CYP4A11 767/4885CYP4Z1 2494/4885 |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | POF1B, ADH1C, OSBP | CYP4F2 57/4885CYP4A11 53/4885CYP4Z1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.